author-photo

Bartlomiej Zerek

20

Papers

17

Citations

Citation Trend

Filter By

Papers (12) Sort By

Journal Conference Others

Novel engineered TRAIL‐based chimeric protein strongly inhibits tumor growth and bypasses TRAIL resistance

2020 International Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (3)
Improved cytotoxicity of novel TRAIL variants produced as recombinant fusion proteins

2018 Protein Engineering Design & Selection
Show All
- Source
- Cite
- Save
Citations (1)
Ewolucja leków biologicznych w kontekście terapii onkologicznej

2018
Show All
- Source
- Cite
- Save
Citations (0)
367 Induction of apoptosis and inhibition of angiogenesis by novel fusion protein – AD-O54.9 as a new preclinical strategy in cancer treatment

2014 European Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (0)
Abstract 2773: AD-O56.9: A fusion of TRAIL/Apo2L with a membrane disrupting peptide as a novel anticancer therapeutic

2014 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
519 AD-O53.2 – novel biological anticancer therapeutic agent with a dual mechanism of action

2014 European Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (0)
Abstract 2600: Preclinical evaluation of the novel fusion molecule with high dual antiangiogenic and anticancer potential

2014 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
AD-O53.2—a novel recombinant fusion protein combining the activities of TRAIL/Apo2L and Smac/Diablo, overcomes resistance of human cancer cells to TRAIL/Apo2L

2014 Investigational New Drugs
Show All
- Source
- Cite
- Save
Citations (6)
467 Two in one – Delivery of apoptotic signal into cancer cells by new class of TRAIL derived, fusion protein

2014 European Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (0)
91 TRAIL\Apo2L-Smac\Diablo Fusion Molecule with High Cytotoxic Activity Against Cancer Cells

2012 European Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (1)